# Pharmacokinetics, Safety, and Tolerability of Lumateperone Long-Acting Injectable in Patients With Schizophrenia

> **NCT04709224** · PHASE1 · COMPLETED · sponsor: **Intra-Cellular Therapies, Inc.** · enrollment: 37 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Lumateperone Long-Acting Injectable

## Key facts

- **NCT ID:** NCT04709224
- **Lead sponsor:** Intra-Cellular Therapies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-30
- **Primary completion:** 2022-05-23
- **Final completion:** 2022-05-23
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2022-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04709224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04709224, "Pharmacokinetics, Safety, and Tolerability of Lumateperone Long-Acting Injectable in Patients With Schizophrenia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04709224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*